AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
Axsome misses Q4 estimates for earnings. Revenues jump 65% on strong Auvelity sales as well as other product sales and top estimates.
Axsome: Q4 Earnings Review: Solid Performance, But Pipeline May Be Overvalued
Axsome Therapeutics, Inc. delivered 66% full-year 2025 revenue growth to $638.5M, driven by Auvelity and Sunosi, but remains loss-making. Despite a robust pipeline and upcoming catalysts, I downgrade AXSM to Hold due to valuation risks and commercial uncertainties in competitive markets. AXSM's 2030 revenue could reach ~$3.5B in a best-case scenario, but achieving blockbuster status for key assets like Sunosi and Symbravo remains uncertain.
Here's What Key Metrics Tell Us About Axsome (AXSM) Q4 Earnings
The headline numbers for Axsome (AXSM) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Should You Buy?
Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026?
Axsome's Auvelity delivered robust 2025 sales growth. A pending FDA decision in 2026 could unlock a broader market and drive sales further.
Axsome Therapeutics: A Conditional Buy Built On SG&A Discipline
Axsome Therapeutics is now a self-sustaining CNS drug company with three marketed products and a robust late-stage pipeline. Revenue visibility anchors downside risk; the investment thesis pivots to execution—specifically, controlling SG&A growth relative to incremental pipeline-driven revenue. Pipeline opportunities in Alzheimer's agitation and narcolepsy could conservatively add $375M+ in annual revenue, but value creation hinges on SG&A discipline.
Strength Seen in Axsome (AXSM): Can Its 4.1% Jump Turn into More Strength?
Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Axsome Therapeutics (AXSM) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
MoneyShow's Best Investment Ideas For 2026: Part 2
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 2 of this series includes Axsome Therapeutics, Berkshire Hathaway, Blackstone, Cal-Maine Foods, and Cassiar Gold Corp., among others.
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out
Biotech companies provide the medical innovations and technological breakthroughs that improve healthcare and can achieve tremendous financial results in the process. However, these names also tend to be highly volatile as a result of the difficult and complex process associated with drug and medical device development as well as the hard-to-navigate regulatory environment.
AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation
Axsome stock jumps as the FDA grants priority review to sNDA for AXS-05 in Alzheimer's agitation, with a decision expected April 30, 2026.
Axsome (AXSM) Stock Jumps 22.8%: Will It Continue to Soar?
Axsome (AXSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
